MST1 and graft versus host disease: Targeting Mst1 and Mst1-mediated signaling pathways that control Th1-dependent cytokine release, IL-2 secretion, and lymphocyte proliferation represents a promising alternative to the current approaches to treat autoimmunity, organ rejection and graft-versus-host disease.